PUBLIC HEALTH PARTNERS
Know the yeast identification method used by your laboratory and its limitations for C. auris identification
Some local public health laboratories offer testing for C. auris identification and confirmation. Contact your local health department for more information.
- Know local, state and regional laboratory resources for C. auris testing. CDPH offers testing for C. auris identification and confirmation. Contact HAIProgram@cdph.ca.gov for more information.
- Perform species identification on all yeast from invasive sources
- Ensure the laboratory notifies infection prevention immediately following a positive result for C. auris, even if preliminary. Early detection of C. auris is essential for containing its spread in healthcare facilities
- Participate in the AR Lab Network Targeted Surveillance Program to access confirmatory identification and antifungal susceptibility testing for non-albicans Candida isolates at no cost. Contact HAIProgram@cdph.ca.gov for more information.
- Know the local epidemiology and prevalence in your region.
- Understand patient risk factors and high risk settings, such as indwelling medical devices in patients residing in high acuity long-term care facilities
- When a patient with C. auris is identified, implement screening of high-risk patients and patient contacts for C. auris colonization. Patients colonized with C. auris may not need medical treatment but can be potential sources of transmission to others.
- Colonization testing services can be accessed at no cost using the CDC Antibiotic Resistance Laboratory Network (AR Lab Network) for patients admitted to a healthcare facility, including in order of priority*:
- High-risk patient contacts of a confirmed C. auris case, such as roommates and other patients residing in the same unit (including for point prevalence surveys (PPS))
- Those admitted from facilities with known C. auris transmission
- Those who are colonized with carbapenemase-producing organisms; prioritize those with non-KPC carbapenemase and requiring high-level care (e.g., indwelling medical devices, mechanical ventilation)
- Those who have recently received healthcare outside the U.S. in the past 12 months, especially where C. auris cases have been reported; prioritize those co-colonized or -infected with carbapenemase-producing organisms
- On a case-by-case basis, those who have exposure to multiple healthcare facilities, particularly long-term care facilities with ventilator units, and especially in regions with C. auris transmission
On a case-by-case basis, preemptive PPS in facilities admitting patients from facilities with known C. auris transmission
- Those who have indwelling medical devices, especially with tracheostomy or on mechanical ventilation
*Availability of AR Lab Network colonization testing resources based on screening priority. Contact your local health department when considering C. auris colonization testing.
- Please contact HAIProgram@cdph.ca.gov for assistance coordinating C. auris colonization testing through the AR Lab Network
Infection Control Measures
- Use adherence monitoring tools to assess and track provider adherence to infection control measures. Monitoring adherence and providing feedback to staff are critical to sustained implementation of infection prevention measures
- During an outbreak, request documentation of adherence monitoring results from affected facility/facilities
- Set expectations for facilities to effectively communicate C. auris status when transferring patients/residents to another healthcare facility
- During an outbreak, consider requesting facilities notify public health of all discharges and transfers involving individuals with C. auris
- Consultation with an infectious disease specialist is highly recommended for patients infected with C. auris. See CDC’s guidance for more detailed treatment information